An Analysis of the PROCLAIM 2007-2012 National Registry
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry.
Clinical Pearls:
- IL-2 is an immunotherapy that can give complete responses that last years
- The database retrospectively looked back over a 5-year period
- The registry showed that IL-2 still gives an occasional, durable response
- The registry also showed that clinical factors such as normal LDH and patient performance status is important in determining who will be successful on IL-2
- Patients with stable disease or did not seem to respond to IL-2 initially had better overall survival than previously thought, according to the registry findings
<<<
Recent Videos
Related Content
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025Article
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
